Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment.

ABSTRACT:

Background

Chronic obstructive pulmonary disease (COPD) affects approximately 15 million people in the United States and accounts for approximately $36 billion in economic burden, primarily due to medical costs. To address the increasing clinical and economic burden, the Global Initiative for Chronic Obstructive Lung Disease emphasizes the use of therapies that help prevent COPD exacerbations, including inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA).

Objective

To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system.

Methods

COPD patients aged 40 years and older who initiated BFC (160/4.5 μg) or FSC (250/50 μg) t

SUBMITTER: Davis JR 

PROVIDER: S-EPMC10397958 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature